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How to starve a tumor 
Jack Taunton 
The formation of new blood vessels, termed 
angiogenesis, is a central process in the evolution of a 
tumor and its subsequent metastasis. Angiogenesls is 
potently inhibited by the fumagillins, a family of epoxide- 
containing natural products. The recent identification of 
a protein target for these compounds may help decipher 
the mechanisms underlying endothelial cell growth. The 
fact that binding is irreversible may inspire the design of 
electrophilic inhibitors of other, poorly understood 
cellular processes. 
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When an unwelcome fungal spore chances to settle down 
and start a family in a mammalian cell culture dish, most of 
us throw away the cells and start again. Not the cell biolo- 
gists in Judah Folkman’s laboratory. Rather than discard a 
contaminated endothelial cell culture as a botched experi- 
ment, Folkman and colleagues decided to pursue the 
curious contaminant in order to understand the basis for its 
remarkable inhibition of endothelial cell growth. Cells 
growing closest to the intruding fungal colony were 
rounded and in various stages of detachment from the 
culture dish, whereas cells more distant from the colony 
appeared healthy, suggesting that the fungus was secreting 
a diffusible growth inhibitory substance into the culture 
medium. Purification of this substance led to the rediscov- 
ery of fumagillin [l], a sesquiterpene diepoxide (Figure 1) 
originally described in the 1950’s as an anti-amoebic agent. 
Pure fumagillin, isolated from the fungal culprit Aspergihs 
jimigutra, inhibits cultured endothelial cell growth at sub- 
nanomolar concentrations, but does not affect many other 
cell types, including a variety of tumor cell lines, at these 
low levels. Presumably reflecting its cytostatic effect on 
endothelial cells in oh, fumagillin also inhibits angiogen- 
esis in rho, the process by which vascular endothelial cells 
develop into new blood vessels. Solid tumors require new 
blood vessels to deliver nutrients and oxygen to the inner 
recesses of the tumor mass, so inhibition of angiogenesis 
represents an indirect way of shutting down tumor growth 
and metastasis. After demonstrating that fumagillin sup- 
presses tumor-induced angiogenesis in who, the Folkman 
laboratory went a step further and, in collaboration with 
scientists at Takeda Industries, synthesized over 100 
fumagillin derivatives. One of these, called AGM-1470 
(Figure 1; also known as TNP-470), is 50 times more 
potent as an inhibitor of endothelial cell growth than 
fumagillin and is less toxic to mice [l]. AGM-1470 is cur- 
rently in phase II clinical trials for the treatment of certain 
types of cancer in humans. 
Small-molecule inhibitors of cell growth are not only poten- 
tially useful drugs, but can also illuminate how specific pro- 
teins are involved in the control of basic cellular processes. 
Two recent papers by Sin et ul. [Z] and Griffith et a/. [3] 
report a biochemical approach to the identification of a can- 
didate molecular target for fumagillin and AGM-1470. Both 
studies make use of a biotinylated derivative of fumagillin 
(Figure 1) to affinity purify the target protein from either 
mouse embryo or bovine brain extracts. The fumagillin- 
binding protein is identified as methionine aminopeptidase 
type 2 (MetAP-Z), a cobalt-dependent enzyme that 
hydrolytically excises the amino-terminal methionine from 
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The chemical structures of fumagillin, AGM-1470 and biotin-fumagillin. 
The arrow indicates the exocyclic epoxide that is susceptible to 
nucleophilic attack. The biotin conjugate is used to affinity purify 
fumagillin-binding proteins from cell extracts. 
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Figure 2 
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Indirect inhibition of protein myristoylation by fumagillin. MetAP-2, in a 
reaction that is inhibited by fumagillin, removes the terminal methionine 
(red) from certain proteins (green). Only once this has occurred can 
N-myristoyl transferase catalyze the ligation of myristate to the amino 
terminus of the prqtein. Many important signaling proteins require 
myristoylation in order to be localized to specific membrane 
compartments within the cell. Improper localization of these proteins 
may be responsible for fumagillin’s cell cycle arrest properties. 
certain proteins. Griffith et al. [3] also show that the 
aminopeptidase activity of purified, recombinant MetAP- 
is abolished by 1 nM fumagillin. 
The biology of methionine aminopeptidases 
Budding yeast have two related methionine aminopepti- 
dases, maplp and map2p. Their functions are partially 
redundant; deletion of either map1 or map2 results in a 
slow-growth phenotype, but deletion of both genes is 
Figure 3 
lethal [4]. Of the two enzymes, map2p clearly shows more 
similarity than maplp to the human MetAP- (59% in the 
catalytic domain compared to 21% for maplp). Sin eta/. [Z] 
and Griffith et al. [3] show that yeast lacking map1 are 
unable to grow in the presence of fumagillin. Conversely, 
a yeast strain that lacks the map2 gene is resistant to 
fumagillin. This result is consistent with the idea that 
fumagillin specifically inhibits type 2 methionine 
aminopeptidase activity in the living yeast cell, thereby 
resulting in growth inhibition. 
Growth-factor-stimulated endothelial cells arrest late in the 
Gl phase of the cell cycle when treated with fumagillin. 
How can the removal of a single methionine residue be so 
important for cell cycle progression and why are endothe- 
ha1 cells more sensitive than other cell types to the inhibi- 
tion of this process? Providing definitive answers to these 
questions will be a challenging task, yet it seems likely that 
a primary cause for cell cycle arrest lies not with inhibition 
of methionine processing per se, but rather with a second 
cotranslational modification, myristic acid attachment. 
Amino-terminal ligation of the 1Ccarbon fatty acid myris- 
tate occurs only when the first amino acid is glycine [S]. 
Hence, N-myristoyl transferase (NMT) will only act on 
nascent polypeptides that have had their amino-terminal 
methionine removed. As many important signaling pro- 
teins need to be myristoylated in order to function in the 
cell, inhibition of protein myristoylation is predicted to 
have dire consequences on cell growth and, indeed, the 
gene encoding yeast NMT is essential for viability [6]. Pro- 
teins known to be myristoylated include the src family 
tyrosine kinases, the small GTPase ARF, the HIV protein 
nef and the ~1 subunit of heterotrimeric G proteins, among 
others. The recent report that hypoxic induction of vascu- 
lar endothelial growth factor (VEGF), an obligate angio- 
genie factor, requires src tyrosine kinases [7] is therefore 
potentially relevant to the study of fumagillin’s anti-angio- 
genie effect. Myristoylation of these proteins is necessary 
(but often not sufficient; see [S]) for their localization to 
specific membrane compartments. It will therefore be 
important to test whether fumagillin results in the aberrant 
localization of various candidate proteins. The idea that 
fumagillin indirectly causes cell cycle arrest by preventing 
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The structure of two epoxide-containing 
(b) protease inhibitors. (a) A cysteine protease 
inhibitor [lo]. tb) An HIV protease 
inhibitor [I I]. 
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Figure 4 
A stereo view of a methionine aminopeptidase 
from E. co/i. Figure adapted with permission 
from [12]. 0 1993 American Chemical 
Society. The 64 amino acid insertion that is 
found only in the type 2 MatAPs is indicated 
by the arrow. 
subcellular localization of important cell proteins (Figure 2) 
has a parallel in the action of the farnesyl transferase 
inhibitors; these inhibitors prevent membrane localization 
of Ras-family small GTPases [8] and are also in clinical 
trials as anticancer drugs. 
The apparent cell type specificity of fumagillin is puzzling 
and still requires explanation. It may be that mammalian 
type 1 and 2 MetAPs have nonredundant functions that 
vary with cell type, resulting in varying degrees of sensi- 
tivity to MetAP- inhibition. One must also consider the 
possibility that MetAP- is the most abundant and there- 
fore most easily detected fumagillin-binding protein in 
the cell, but that it does not, in fact, mediate fumagillin’s 
anti-proliferative effects. A BLAST search for proteins 
related in sequence to human MetAP- retrieves a nuclear 
protein p38 (smallest sum probability 10-r7) of unknown 
function; expression of this protein varies with the cell 
cycle and is detected only in cells that are actively prolifer- 
ating [9]. Might this protein also be targeted by fumag- 
illin? Regardless, the data presented by Griffith et al. [3] 
and Sin ef a/. [Z] clearly show that fumagillin targets 
MetAP- with high, if not absolute, specificity. 
Figure 5 
The chemical structures of trapoxin B and 
lactacystin, two natural products that are 
highly specific, irreversible inhibitors of their 
respective protein targets. 
Lactacystin 
The chemistry of epoxide inhibitors 
A fascinating chemical detail revealed by the recent 
papers is the fact that fumagillin binds irreversibly to 
MetAP-2, suggesting that an active site nucleophile 
attacks fumagillin at its less hindered exocyclic epoxide 
(see arrow in Figure 1). Note also that the more potent 
inhibitor, AGM-1470, with its chloroacetyl carbamoyl 
group, has two electrophilic sites. How is specific recogni- 
tion achieved by this ensemble of 15 carbon atoms in a 
concentrated sea of thousands of competing nucleophiles 
and hydrophobic surfaces? The epoxide functionality is a 
finely tuned electrophile and does not yield readily to 
nucleophilic attack. Rather, reactions with physiological 
nucleophiles that open the epoxide ring are expected to 
be extremely slow in the absence of general acid or Lewis 
acid catalysis. An example is provided by the simple pep- 
tidic epoxide shown in Figure 3a, an irreversible cysteine 
protease inhibitor [lo]. Reaction of this epoxide with the 
catalytic cysteine residue in papain occurs -10s times 
faster than with cysteine itself. Furthermore, the rate of 
papain inactivation is strongly affected by additional struc- 
tural elements in the inhibitor, including the absolute con- 
figuration of each chiral center. Another example is the 
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HIV protease inhibitor reported by Yu ef al. [ll] 
(Figure 3b). This epoxide alkylates the catalytic aspartic 
acid (Asp25), a reaction that is likely to be accelerated by 
epoxide protonation by Asp125. Shape-selective hydro- 
phobic interactions are therefore predicted to orient 
fumagillin’s epoxide in close proximity to an active site 
nucleophile as well as a general or Lewis acid, contribut- 
ing substantially to the observed kinetic selectivity in the 
alkylation of MetAP-2. Consistent with this, Griffith et al. 
[3] report a fumagillin analog that lacks the terminal 
epoxide but still binds MetAP- and inhibits cell growth, 
albeit at micromolar rather than picomolar concentrations. 
Although the atomic details of a fumagillin-MetAP- 
complex await a high resolution structure determination, 
the known crystal structure of a related methionine 
aminopeptidase from Eschetio?ia co/i offers some clues 
about structural elements that are involved in catalysis and 
that may be important in the covalent attachment of 
fumagillin to MetAP- (Figure 4) [12]. Catalysis by all 
verAI% is metal-dependent and the crystal structure of E. 
co/i MetAP reveals that the two active site cobalt atoms are 
ligated by two aspartic acids, a histidine, and two glutamic 
acids, all of which are conserved in human MetAP- [13]. 
Although the precise function of the two cobalt atoms and 
their ligands in promoting amide bond hydrolysis is 
unknown, it would be interesting to test whether alkyla- 
tion of MetAP- by fumagillin is metal-dependent, imply- 
ing a role for cob,alt as a Lewis acid in the activation of the 
epoxide. It is also possible that one of the metal ligands 
(Asp, Glu or His) acts as a nucleophile, a scenario that has 
precedents in abiological metal-promoted epoxide reac- 
tions [14]. Finally, Sin etaI. [Z] suggest another plausible 
nucleophile, Cys416 (human MetAP- numbering), which 
lies in a 64 amino acid insertion (see arrow, Figure 4) found 
only in the type 2 MetAPs. Alkylation of this cysteine by 
fumagillin would be consistent with the observation that 
human MetAP- peptidase activity is sensitive to cysteine- 
modifying reagents and would also explain why yeast 
maplp is not inhibited by fumagillin. It is unclear whether 
this cysteine is located near the active site, however, and it 
is of course possible that fumagillin alkylates an amino acid 
that is not directly involved in catalysis, as is observed in 
the acetylation of cyclooxygenase by aspirin [ 151. 
Fumagillin is not alone in its mode of inhibition. Lacta- 
cystin, which binds irreversibly to the proteasome [16], 
and trapoxin, an irreversible histone deacetylase inhibitor 
[17] (Figure 5), are similar to fumagillin in that they are 
chemically reactive natural products that nonetheless alky- 
late or acylate their protein targets with incredible speci- 
ficity. These compound 
s’ 
are the product of the evolved 
ecosystems of diverse microbes, but might in the future 
inspire the design of synthetic small-molecule libraries 
that exploit electrophilic functionality, like that of the 
epoxide, as a molecular recognition element distinct from 
recognition elements based only on hydrogen bonding and 
hydrophobic/aromatic interactions. Such libraries might 
have particular advantages in the continuing hunt for 
drugs with higher potencies and selectivities. 
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